164 related articles for article (PubMed ID: 21978107)
21. Measles: not just another viral exanthem.
Duke T; Mgone CS
Lancet; 2003 Mar; 361(9359):763-73. PubMed ID: 12620751
[TBL] [Abstract][Full Text] [Related]
22. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
23. A benefit-cost analysis of two-dose measles immunization in Canada.
Pelletier L; Chung P; Duclos P; Manga P; Scott J
Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
[TBL] [Abstract][Full Text] [Related]
24. [Alterations in epidemics and vaccination for measles during a 20 year period and a strategy for elimination in Kurashiki City, Japan].
Terada K; Niizuma T; Ogita S; Kataoka N
Kansenshogaku Zasshi; 2002 Mar; 76(3):180-4. PubMed ID: 11974886
[TBL] [Abstract][Full Text] [Related]
25. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated.
Sugerman DE; Barskey AE; Delea MG; Ortega-Sanchez IR; Bi D; Ralston KJ; Rota PA; Waters-Montijo K; Lebaron CW
Pediatrics; 2010 Apr; 125(4):747-55. PubMed ID: 20308208
[TBL] [Abstract][Full Text] [Related]
26. The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium).
Beutels P; Van Damme P; Van Casteren V; Gay NJ; De Schrijver K; Meheus A
Vaccine; 2002 Oct; 20(29-30):3551-9. PubMed ID: 12297401
[TBL] [Abstract][Full Text] [Related]
27. Outbreaks spur measles vaccine studies.
Hampton T
JAMA; 2011 Dec; 306(22):2440-2. PubMed ID: 22166599
[No Abstract] [Full Text] [Related]
28. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
Hagedorn BL; Dabbagh A; McCarthy KA
Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
[TBL] [Abstract][Full Text] [Related]
29. Strategic planning for measles control: using data to inform optimal vaccination strategies.
Simons E; Mort M; Dabbagh A; Strebel P; Wolfson L
J Infect Dis; 2011 Jul; 204 Suppl 1():S28-34. PubMed ID: 21666174
[TBL] [Abstract][Full Text] [Related]
30. Cost analysis of measles in refugees arriving at Los Angeles International Airport from Malaysia.
Coleman MS; Burke HM; Welstead BL; Mitchell T; Taylor EM; Shapovalov D; Maskery BA; Joo H; Weinberg M
Hum Vaccin Immunother; 2017 May; 13(5):1084-1090. PubMed ID: 28068211
[TBL] [Abstract][Full Text] [Related]
31. A model to estimate the potential economic benefits of measles eradication for the United States.
Miller MA; Redd S; Hadler S; Hinman A
Vaccine; 1998 Dec; 16(20):1917-22. PubMed ID: 9796043
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of workplace vaccination against measles.
Coppeta L; Morucci L; Pietroiusti A; Magrini A
Hum Vaccin Immunother; 2019; 15(12):2847-2850. PubMed ID: 31339463
[TBL] [Abstract][Full Text] [Related]
33. Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003.
Filia A; Brenna A; Panà A; Cavallaro GM; Massari M; Ciofi degli Atti ML
BMC Public Health; 2007 Jul; 7():169. PubMed ID: 17650298
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015.
Ramsay LC; Crowcroft NS; Thomas S; Aruffo E; Teslya A; Heffernan JM; Gournis E; Hiebert J; Jaeger V; Jiaravuthisan M; Sharron J; Severini A; Deeks SL; Gubbay J; Mazzulli T; Sander B
Euro Surveill; 2019 Mar; 24(11):. PubMed ID: 30892178
[TBL] [Abstract][Full Text] [Related]
36. Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.
Adhikari BB; Goodson JL; Chu SY; Rota PA; Meltzer MI
Drugs R D; 2016 Dec; 16(4):327-338. PubMed ID: 27696306
[TBL] [Abstract][Full Text] [Related]
37. Health impact of measles vaccination in the United States.
Bloch AB; Orenstein WA; Stetler HC; Wassilak SG; Amler RW; Bart KJ; Kirby CD; Hinman AR
Pediatrics; 1985 Oct; 76(4):524-32. PubMed ID: 3931045
[TBL] [Abstract][Full Text] [Related]
38. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination.
Garrison LP; Bauch CT; Bresnahan BW; Hazlet TK; Kadiyala S; Veenstra DL
J Infect Dis; 2011 Jul; 204 Suppl 1():S124-32. PubMed ID: 21666153
[TBL] [Abstract][Full Text] [Related]
39. [An economic evaluation of measles vaccination in District 3 of the city of Bucharest].
Ion-Nedelcu N; Mihăileanu C; Dobrescu A
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1989; 34(2):163-8. PubMed ID: 2506626
[TBL] [Abstract][Full Text] [Related]
40. [Health and economic benefits of mandatory regular vaccination in Slovakia. IV. Measles, rubella and mumps].
Hudecková H; Straka S; Avdicová M; Rusnáková S
Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):31-5. PubMed ID: 11233671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
